Please assess the completion status of the following clinical trial:

Trial Title: Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria.~* Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures.~Exclusion Criteria:~* Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder.~* Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor~* Participation in another trial that affects the primary outcome without prior approval~* Physician/provider or patient refusal~* Participation in this trial in a prior pregnancy~* Triplet or higher order pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine 30MG (Type: ACTIVE_COMPARATOR): Oral administration of 30mg Nifedipine XL q24 hours until delivery
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo group q24hrs until delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).